RxDoctor Payments Data

Scott Nesbitt, MD

Family Medicine · Butler, PANPI 1962419861

Payments from drug & device makers

$8,527in general payments, 2019–2025

Across 484 payments — averaging $17.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • GSK$894
  • Lilly USA, LLC$857
  • AbbVie$768
  • AstraZeneca$736
  • Amgen$524
  • plus $4K from 35 others

What the payments were for

  • Food & beverage$8,44399%
  • Education$831%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,527 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$51,244
Medicare patients
121
Services billed
628

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide115$152,035
EliquisApixaban85$83,637
TrulicityDulaglutide38$64,664
JardianceEmpagliflozin61$45,125
Synjardy XrEmpagliflozin/Metformin Hcl27$29,192
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$24,477
FarxigaDapagliflozin Propanediol22$19,687
XareltoRivaroxaban14$17,430
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr18$11,797
MyrbetriqMirabegron11$10,030
SynthroidLevothyroxine Sodium126$7,760
LivaloPitavastatin Calcium15$5,196
Ezetimibe139$3,531
Pitavastatin Calcium25$3,170
Rosuvastatin Calcium236$2,797

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,024$152,035115 claims
PfizerEliquis$384$83,63785 claims
Boehringer IngelheimJardiance, Synjardy Xr$290$74,31788 claims
Lilly USA, LLCTrulicity$857$64,66438 claims
GSKTrelegy Ellipta, Anoro Ellipta$894$36,27446 claims
AstraZenecaFarxiga$736$19,68722 claims
Johnson & JohnsonXarelto$285$17,43014 claims
AbbVieSynthroid$768$7,760126 claims
Kowa Pharmaceuticals America, Inc.Livalo$187$5,19615 claims
Hikma Pharmaceuticals USABuprenorphine$43$2,36211 claims
Almatica Pharma LLCSertraline Hcl$16$1,279147 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Butler

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →